Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15222058 | 1.00 | MAOA (0.43) | MAOAMAOBLIPENOTUMIDO1 | |
| SCHEMBL8030397 | 1.00 | MAOA (0.43) | MAOAMAOBLIPENOTUMIDO1 | |
| SCHEMBL19121066 | 0.79 | DRD2 (0.55) | MAOAMAOBPRCP | |
| SCHEMBL17662597 | 0.79 | DRD2 (0.55) | MAOAMAOBPRCP | |
| Hydrochloric Acid SCHEMBL11458075 | 0.78 | DRD2 (0.54) | MAOAMAOBPRCP | |
| SCHEMBL26638792 | 0.77 | NOTUM (0.41) | MAOAMAOBLIPENOTUMIDO1 | |
| SCHEMBL17554525 | 0.77 | MAOA (0.42) | MAOAMAOBNOTUMOPRM1OPRL1 | |
| SCHEMBL19406895 | 0.76 | HTR2A (0.40) | — | |
| Hydrochloric Acid SCHEMBL7552914 | 0.75 | IDO1 (0.45) | MAOAMAOBLIPENOTUMIDO1 | |
| SCHEMBL26956169 | 0.75 | PNMT (0.49) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| EP-1957518-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-8252895-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252895-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-7872097-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872097-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20090170755-A1 | Cyclic Peptide Compounds | ASTELLAS PHARMA INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170755-A1 | Cyclic Peptide Compounds | ASTELLAS PHARMA INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1592684-B1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170755-A1 | Cyclic Peptide Compounds | VIP, HAVCR2, EIF2AK2 | MAOA 4850/4885MAOB 4801/4885LIPE 2365/4885 |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, EIF2AK2 | MAOA 4869/4885MAOB 4832/4885LIPE 2380/4885 |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | MAOA 664/4885MAOB 734/4885LIPE 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.